翰森制药(03692) - 2023 - 年度业绩

Financial Performance - The company reported a revenue of approximately RMB 10.104 billion for the year ending December 31, 2023, representing a growth of about 7.7% compared to the previous year[1]. - Profit for the year was approximately RMB 3.278 billion, reflecting a growth of about 26.9% compared to the previous year[1]. - Earnings per share were approximately RMB 0.55, an increase of about 26.6% from the previous year[1]. - Gross profit for the same period was RMB 9,072.943 million, up from RMB 8,515.400 million in the previous year, indicating a gross margin improvement[38]. - The company reported a total comprehensive income of RMB 3,705.424 million for the year, compared to RMB 3,216.633 million in 2022, marking an increase of approximately 15.2%[39]. - The company achieved a net profit of RMB 3,277.503 million for the year, compared to RMB 2,583.747 million in 2022, reflecting a year-over-year increase of approximately 27%[39]. - The company's income tax expense for 2023 was RMB 488,652,000, an increase of 34.1% from RMB 364,681,000 in 2022[50]. - The company declared a total dividend of approximately RMB 652,843,000 for 2023, compared to RMB 713,265,000 in 2022, reflecting a decrease of 8.5%[51]. Revenue Breakdown - Sales revenue from innovative drugs and collaborative products reached approximately RMB 6.865 billion, an increase of about 37.1%, accounting for approximately 67.9% of total revenue, up from 53.4% in the previous year[1]. - The revenue from the oncology segment was approximately RMB 6.169 billion, accounting for about 61.0% of total revenue[10]. - The revenue from the anti-infection segment was approximately RMB 1.269 billion, accounting for about 12.6% of total revenue[10]. - Revenue from customer contracts and product sales amounted to RMB 9,403,962 thousand, up from RMB 9,298,594 thousand in the previous year[47]. Research and Development - Research and development expenses were approximately RMB 2.097 billion, a growth of about 23.8%, representing about 20.8% of total revenue[1]. - The company has over 30 innovative drug projects at various stages of research and development, indicating a strong pipeline for future growth[9]. - The company plans to continue expanding its innovative drug portfolio and has several clinical trials underway for new treatments[3]. - The company is conducting over 50 clinical trials across more than 30 innovative drug products, with eight new drugs entering clinical stages in mainland China during the reporting period[24]. Product Approvals and Collaborations - The company received approval for six new products during the reporting period, including one innovative drug with two approved indications[2]. - The company has a total of seven innovative drugs approved for listing, all included in the National Medical Insurance Catalogue[2]. - The company entered into an exclusive cooperation agreement with Antengene Corporation for the commercialization of selinexor in mainland China[4]. - The company developed a new drug, HS-20105, which received clinical trial approval for the treatment of advanced solid tumors[5]. - The company received clinical trial approval for the innovative drug HS-10511, intended for the treatment of hypertrophic cardiomyopathy (HCM)[6]. - The company entered into a licensing agreement with GSK for the global exclusive rights to develop, manufacture, and commercialize HS-20089, a novel B7-H4 targeted antibody-drug conjugate (ADC)[6]. Market Presence and Strategy - The company plans to continue expanding its market presence in China, where over 90% of its revenue is generated[45]. - The company aims to achieve carbon neutrality by 2055 and has enhanced its environmental goals for 2030[31]. - The company plans to enhance innovation and accelerate the commercialization of R&D outcomes to meet unmet medical needs in China and globally[37]. Financial Position and Assets - As of December 31, 2023, the company had cash and bank deposits of RMB 22.435 billion, an increase from RMB 17.615 billion in the previous year[33]. - The company's debt-to-asset ratio was approximately 21.9% as of December 31, 2023, down from 24.5% the previous year[33]. - Total assets as of December 31, 2023, were RMB 25,794,773 thousand, compared to RMB 22,646,944 thousand in 2022, reflecting a growth of 13.5%[41]. - Non-current liabilities decreased to RMB 381,457 thousand from RMB 4,735,433 thousand, indicating a substantial reduction[41]. Employee and Governance - The company had a total of 9,123 employees as of December 31, 2023, with employee costs amounting to approximately RMB 2,681.81 million for the year[36]. - The company has adopted a corporate governance code and believes it has complied with all relevant provisions during the reporting period, except for the separation of roles between the chairman and CEO[62]. - The audit committee, consisting of three independent non-executive directors, reviewed the audited results for the year ending December 31, 2023, ensuring compliance with accounting principles[65]. Shareholder Information - The company issued 11,000,000 new shares under the restricted share unit plan at an issue price of HKD 2.29 per share, with the market price on the previous trading day being HKD 14.96[36]. - The proposed final dividend for the year ending December 31, 2023, is HKD 0.1422 per share, significantly higher than HKD 0.05 per share in 2022, marking a 184.4% increase[66]. - The company suspended share transfer registration from June 21, 2024, to June 25, 2024, to determine shareholder eligibility for the proposed final dividend[67].